Ratios

		vs industry	vs history
P/B	1.50	OXGN's P/B is ranked higher than 83% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 3.80 vs. OXGN: 1.50 )	OXGN' s 10-Year P/B Range Min: 0.09   Max: 18.47 Current: 1.5 0.09 18.47
P/S	27.50	OXGN's P/S is ranked lower than 80% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 6.90 vs. OXGN: 27.50 )	OXGN' s 10-Year P/S Range Min: 1.24   Max: 18798.5 Current: 27.5 1.24 18798.5
EV-to-EBIT	34.5	OXGN's EV-to-EBIT is ranked higher than 58% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 14.61 vs. OXGN: 34.5 )	OXGN' s 10-Year EV-to-EBIT Range Min: 1.6   Max: 5.4 Current: 34.5 1.6 5.4

Valuation & Return

		vs industry	vs history
Price/Net Cash	1.6	OXGN's Price/Net Cash is ranked higher than 66% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 8.80 vs. OXGN: 1.6 )	OXGN' s 10-Year Price/Net Cash Range Min: 1.5   Max: 7.2 Current: 1.6 1.5 7.2
Price/Net Current Asset Value	2.5	OXGN's Price/Net Current Asset Value is ranked lower than 55% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 32.60 vs. OXGN: 2.5 )	OXGN' s 10-Year Price/Net Current Asset Value Range Min: 0.1   Max: 2.9 Current: 2.5 0.1 2.9
Price/Tangible Book	1.5	OXGN's Price/Tangible Book is ranked lower than 61% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 4.70 vs. OXGN: 1.5 )	OXGN' s 10-Year Price/Tangible Book Range Min: 1.1   Max: 6.9 Current: 1.5 1.1 6.9
Price/Median PS Value	0.1	OXGN's Price/Median PS Value is ranked lower than 58% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 0.90 vs. OXGN: 0.1 )	OXGN' s 10-Year Price/Median PS Value Range Min: 0.1   Max: 8 Current: 0.1 0.1 8
Forward Rate of Return (Yacktman)	-3850.4	OXGN's Forward Rate of Return (Yacktman) is ranked lower than 54% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: -4.65 vs. OXGN: -3850.4 )	OXGN' s 10-Year Forward Rate of Return (Yacktman) Range Min: -30.7   Max: -19.2 Current: -3850.4 -30.7 -19.2

Business Description

OxiGene, Inc was incorporated in 1988 in the state of New York and reincorporated in 1992 in the State of Delaware. OxiGene is a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. Its main focus is the development of product candidates referred to as vascular disrupting agents, or VDAs, that selectively disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival and also are associated with visual impairment in a number of ophthalmological diseases and conditions. The Company intends to primarily target the development of its product candidates for the treatment of rare cancers that would be eligible for orphan drug status from the Food and Drug Administration, or FDA. The Company's main candidate, ZYBRESTAT, has been awarded orphan drug status by the FDA and the European Commission in the European Union for the treatment of advanced anaplastic thyroid cancer, or ATC, and for the treatment of medullary, Stage IV papillary and Stage IV follicular thyroid cancers. The FDA has also granted Fast Track status to ZYBRESTAT for the treatment of regionally advanced and/or metastatic ATC, as well as in ovarian cancer. An orphan drug is defined as a product that treats a rare disease affecting fewer than 200,000 patients in the United States. ZYBRESTAT is a reversible tubulin binding agent that works by disrupting the network of blood vessels within solid tumors. The Company's competitors in the development of VDAs are Sanofi-Aventis, Myrexis, Nereus and MediciNova. The Company's product candidates are subject to extensive governmental regulations relating to development, clinical trials, manufacturing, oversight of clinical investigators, recordkeeping and commercialization.
Company Website
SEC Reports

Industry:	Biotechnology
Compare:	NVO, AMGN, GILD, BIIB, CELG

» More Articles for OXGN

Headlines

Articles On GuruFocus.com

OXiGENE Inc. Reports Operating Results (10-Q) May 14 2010

OXiGENE Inc. Reports Operating Results (10-Q) Nov 10 2009

OXiGENE Inc. Reports Operating Results (10-Q) Aug 13 2009

OXiGENE Inc. Reports Operating Results (10-Q) May 15 2009

Personalized Checklist